Skip to main content
About Us
Switch Language
English
Spanish
Thrombosis
Adviser
This website is intended to provide information to an international audience outside the USA and UK
I am a Healthcare Professional
I am a Patient
Thrombosis
Adviser
for Healthcare Professionals
Knowledge Base
Essentials
Introduction
Haemostasis
The Coagulation Cascade
Introduction
Factor Xa Inhibitors
Direct Thrombin Inhibitors
Vitamin K Antagonists
Heparins
Thrombus Formation
Venous Thrombosis
Arterial Thrombosis
Stroke Prevention
Atrial Fibrillation-Related Stroke
Introduction to AF
Prevention
Preventing AF-Related Stroke
Patients with NVAF
Anticoagulant Therapy
Antiplatelet Therapy
Anticoagulation and Cardiac Procedures
Other Options
Patients with VAF
Pharmacological Therapy
Surgery
Special Populations
Older Patients with AF
Patients with AF and diabetes
Patients with AF undergoing PCI
Patients with Renal Impairment
Patients with Worsening Renal Function
Venous Thrombosis
Introduction
Prevention
Introduction
Anticoagulant Therapy for Venous Thromoembolism Prevention
Other Options
Deep Vein Thrombosis & Pulmonary Embolism
Deep VT Introduction and Diagnosis
Pulmonary Embolism Introduction and Diagnosis
Treatment
Extended Treatment
Complications
VTE in Special Populations
Patients with VTE and Renal Impairment
Paediatric VTE
Frail and Elderly Patients with VTE
Cancer-Associated Thrombosis
Introduction to Cancer-Associated Thrombosis
Treatment and Prevention of Recurrent Events
Arterial Thrombosis
Acute Coronary Syndrome
Introduction
Treatment
Secondary Prevention
Coronary Artery Disease (CAD)
Peripheral Artery Disease (PAD)
Glossary
Latest In Thrombosis
Thrombosis Digest
2021
International Conference on Thrombosis and Hemostasis Issues in Cancer 2021
2020
When is the right time to start thinking about renal function in patients with AF?
Thrombosis Adviser at the European Society of Cardiology Congress 2020
Extended Treatment for VTE: Tailoring Treatment for Patients Who Need it
Patients with diabetes and atrial fibrillation: How can the risk of cardiovascular death be reduced?
Managing anticoagulation during the COVID-19 pandemic
Supporting the treatment of patients with low-risk pulmonary embolism at home
The importance of real-world evidence: A look at stroke prevention in atrial fibrillation
Keeping it simple: Single drug approaches to VTE treatment
The importance of preserving kidney function in atrial fibrillation
Where next in cancer-associated thrombosis?
Time for a change? Switching anticoagulants in patients with AF or VTE
High-risk patients with atrial fibrillation: The importance of protection
Understanding the risk of VTE recurrence: Who needs extended anticoagulation?
ESC Heart and Stroke Conference: Highlights from Bayer 24–25 January 2020
